Study of a scout dose of resin microspheres for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial is testing a low 'scout' dose of tiny radioactive beads (resin microspheres) given into the liver to treat liver cancer. The goal is to see if this approach is safe and helps patients with certain types of liver cancer that cannot be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years or older.
- You have liver cancer (hepatocellular carcinoma, intrahepatic cholangiocarcinoma, or cancer that has spread from elsewhere to the liver).
- At least 30% of your normal (non-cancer) liver tissue is not in the treatment area.
- Your liver function is good (Child-Pugh class A).
- You are able to care for yourself and perform daily activities (ECOG score 0 or 1).
- You have adequate blood counts and organ function (e.g., white blood cells, hemoglobin, platelet count, bilirubin, liver enzymes, and kidney function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a treatment called radioembolization for small liver cancers. Radioembolization delivers tiny radioactive beads to the tumor, and the goal is to see if it helps shrink or control the cancer.
This trial tests a targeted internal radiation treatment for people with liver cancer (HCC) that is too widespread for surgery and goes beyond the up-to-7 criteria. It aims to see if this therapy can safely and effectively treat tumors that are all located in a specific area of the liver.
This trial tests two different ways to treat liver cancer that can't be removed with surgery. It compares stereotactic body radiation therapy (targeted high-dose radiation) with selective internal radiation therapy (tiny radioactive beads delivered through a blood vessel), both combined with immunotherapy (medicines that help your immune system fight cancer).
This trial is for people with liver cancer (hepatocellular carcinoma) who are about to receive a type of internal radiation therapy called TARE (also known as radioembolization). Researchers want to learn more about how the cancer responds to this treatment using scans and biopsies. You might be a good fit if you have not had any prior treatment for your liver cancer.
This trial tests a new type of MRI scan (hyperpolarized 13C-MRI) in people with liver cancer who are already receiving radiation therapy, atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy). The goal is to see if the scan can help doctors better understand how the cancer responds to treatment.
This trial tests a streamlined way to deliver radioactive beads (radioembolization) directly to liver tumors in people with metastatic liver cancer or bile duct cancer. It aims to make treatment simpler and safer while still effectively targeting tumors.
Hear when a new Radioembolization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.